rna
interfer
rnai
gain
intern
attent
fire
mello
colleagu
discov
abil
doublestrand
rna
silenc
gene
express
nematod
worm
caenorhabd
elegan
three
year
later
tuschl
cowork
publish
celebr
proofofprincipl
experi
demonstr
synthet
small
interf
rna
sirna
could
achiev
sequencespecif
gene
knockdown
mammalian
cell
line
first
success
use
sirna
gene
silenc
mice
achiev
hepat
c
target
shortli
thereaft
sinc
time
biotechnolog
sector
made
consider
effort
advanc
sirna
therapeut
treatment
variou
diseas
target
includ
viral
infect
cancer
rnai
fundament
pathway
eukaryot
cell
sequencespecif
sirna
abl
target
cleav
complementari
mrna
rnai
trigger
presenc
long
piec
doublestrand
rna
cleav
fragment
known
sirna
nucleotid
long
enzym
dicer
practic
sirna
synthet
produc
directli
introduc
cell
thu
circumv
dicer
mechan
fig
shortcut
reduc
potenti
innat
immun
interferon
respons
shutdown
cellular
protein
express
occur
follow
interact
long
piec
nucleotid
doublestrand
rna
intracellular
rna
receptor
sirna
present
cytoplasm
cell
incorpor
protein
complex
call
rnainduc
silenc
complex
risc
argonaut
multifunct
protein
contain
within
risc
unwind
sirna
sens
strand
passeng
strand
sirna
cleav
activ
risc
contain
antisens
strand
guid
strand
sirna
select
seek
degrad
mrna
complementari
antisens
strand
fig
cleavag
mrna
occur
posit
nucleo
tide
complementari
antisens
strand
rel
activ
risc
complex
move
destroy
addit
mrna
target
propag
gene
silenc
extra
potenc
ensur
therapeut
effect
day
rapidli
divid
cell
sever
week
nondivid
cell
eventu
sirna
dilut
certain
therapeut
threshold
degrad
within
cell
repeat
administr
necessari
achiev
persist
effect
theoret
use
appropri
design
sirna
rnai
machineri
exploit
silenc
nearli
gene
bodi
give
broader
therapeut
potenti
typic
smallmolecul
drug
inde
alreadi
report
synthet
sirna
capabl
knock
target
variou
diseas
vivo
includ
hypercholesterolaemia
liver
cirr
hosi
hepat
b
viru
hbv
human
papillomaviru
ovarian
cancer
bone
cancer
order
advanc
implement
clinic
set
safe
effect
deliveri
system
must
develop
nake
chemic
modifi
sirna
shown
efficaci
certain
physiolog
set
brain
lung
mani
tissu
bodi
requir
addit
deliveri
system
facilit
transfect
nake
sirna
subject
degrad
endogen
enzym
larg
kda
neg
charg
cross
cellular
membran
strand
sirna
molecul
complementari
target
mrna
activ
risc
import
role
target
mrna
identif
destruct
process
deliv
nucleic
acid
materi
cell
issu
effect
nontox
deliveri
key
challeng
serv
signific
barrier
sirna
technolog
therapeut
applic
eas
sirna
deliveri
partli
depend
access
target
organ
tissu
within
bodi
local
sirna
deliveri
applic
sirna
therapi
directli
target
tissu
offer
sever
benefit
includ
potenti
higher
bioavail
given
proxim
target
tissu
reduc
advers
effect
typic
associ
system
administr
contrast
system
deliveri
mean
intraven
inject
deliveri
particl
travel
throughout
bodi
target
organ
tissu
requir
particl
abil
avoid
uptak
clearanc
nontarget
tissu
fig
sever
tissu
amen
topic
local
therapi
includ
eye
skin
mucu
membran
local
tumour
tabl
local
sirna
deliveri
particularli
wellsuit
treatment
lung
diseas
infect
direct
instil
sirna
lung
intranas
intratrach
rout
enabl
direct
contact
lung
epitheli
cell
cell
play
part
myriad
lung
condit
infect
includ
cystic
fibrosi
asthma
influenza
common
cold
report
respiratori
syncyti
viru
rsv
replic
inhibit
nasal
administ
sirna
formul
without
transfect
agent
mice
progress
treatment
rsv
continu
phase
ii
clinic
trial
use
aerosol
sirna
deliveri
system
intratrach
administr
sirna
also
report
offer
prophylact
therapeut
effect
treatment
sever
acut
respiratori
syndrom
anoth
exampl
local
deliveri
direct
intratumor
inject
sirna
deliveri
complex
variou
mous
xenograft
model
sirna
complex
deliveri
agent
polyethyleneimin
pei
shown
inhibit
tumour
growth
upon
intratumor
inject
mice
bear
glioblastoma
xenograph
niu
cowork
also
report
nake
sirna
efficaci
direct
inject
subcutan
cervic
cancer
model
mice
contrast
direct
access
local
target
mani
tissu
reach
system
administr
deliveri
agent
bloodstream
sirna
formul
system
applic
face
seri
hurdl
vivo
reach
cytoplasm
target
cell
fig
postinject
sirna
complex
must
navig
circulatori
system
bodi
avoid
kidney
filtrat
uptak
phagocyt
aggreg
serum
protein
enzymat
degrad
endogen
nucleas
phagocytosi
serv
signific
immunolog
barrier
bloodstream
also
extracellular
matrix
tissu
phagocyt
cell
macrophag
monocyt
remov
foreign
materi
bodi
protect
infect
virus
bacteria
fungi
unfortun
phagocyt
also
highli
effici
remov
certain
therapeut
nanocomplex
macromolecul
bodi
step
must
taken
avoid
opson
design
drug
deliveri
vehicl
egress
bloodstream
across
vascular
endotheli
barrier
pose
signific
challeng
deliveri
sirna
mani
tissu
within
bodi
gener
molecul
larger
nm
diamet
readili
cross
capillari
endothelium
therefor
remain
circul
clear
bodi
certain
tissu
howev
allow
entri
larger
molecul
includ
liver
spleen
tumour
organ
allow
passag
molecul
nm
diamet
accommod
typic
drug
deliveri
nanocarri
introduc
cytoplasm
cleav
small
interf
rna
sirna
enzym
dicer
altern
sirna
introduc
directli
cell
sirna
incorpor
rnainduc
silenc
complex
risc
result
cleavag
sens
strand
rna
argonaut
activ
riscsirna
complex
seek
bind
degrad
complementari
mrna
lead
silenc
target
gene
activ
riscsirna
complex
recycl
destruct
ident
mrna
target
sirna
complex
leav
bloodstream
must
diffus
extracellular
matrix
dens
network
polysaccharid
fibrou
protein
creat
resist
transport
macromolecul
nanoparticl
slow
even
halt
drug
deliveri
process
creat
addit
opportun
nanoparticl
taken
resid
macrophag
taken
target
cell
particl
must
escap
endosom
reach
cytoplasm
sirna
nanocomplex
unabl
exit
endosom
traffick
endomembran
compart
decreas
ph
subject
degrad
condit
lysosom
final
formul
deliveri
agent
sirna
must
releas
carrier
cellular
machineri
modifi
sirna
improv
deliveri
human
evolv
number
hostdef
mechan
sirna
featur
certain
viral
infect
howev
chemic
modif
introduc
sirna
molecul
evad
immun
defenc
vivo
exampl
mani
nonmodifi
sirna
induc
nonspecif
activ
immun
system
tolllik
receptor
pathway
effect
reduc
incorpor
modif
sugar
structur
select
nucleotid
within
sens
antisens
strand
fig
modif
also
shown
confer
resist
endo
nucleas
activ
abrog
offtarget
effect
incorpor
seed
region
correspond
nucleotid
antisens
strand
common
modif
approach
mitig
enzymat
degrad
includ
introduct
phosphorothio
backbon
linkag
rna
strand
reduc
suscept
exonucleas
also
possibl
incorpor
altern
sugar
modif
exampl
fluorin
substitut
increas
resist
endonucleas
anoth
strategi
improv
therapeut
efficaci
sirna
involv
conjug
small
molecul
peptid
sens
strand
sirna
sever
small
molecul
report
increas
targetgen
knockdown
vitro
includ
membraneperm
peptid
polyethylen
glycol
peg
particular
note
cholesterolmodifi
sirna
demonstr
increas
bind
serum
albumin
result
improv
biodistribut
certain
target
includ
liver
fig
cholesterolmodifi
sirna
capabl
silenc
apolipoprotein
b
apob
target
mous
liver
jejunum
ultim
reduc
total
cholesterol
level
anoth
studi
difiglia
cowork
detail
abil
cholesterolmodifi
sirna
knockdown
gene
associ
huntington
diseas
singl
intrastriat
inject
abl
delay
abnorm
behaviour
phenotyp
observ
rapidonset
mous
model
diseas
given
success
cholesterolmodifi
sirna
vivo
wolfrum
cowork
attempt
identifi
altern
lipidlik
molecul
serv
rna
conjug
improv
deliveri
sirna
specif
fatti
acid
bilesalt
deriv
conjug
sirna
inject
mice
hamster
order
elucid
modifi
sirna
conjug
interact
highdens
lipoprotein
hdl
lowdens
lipoprotein
ldl
receptor
enabl
deliveri
liver
found
shorter
fattyacid
chain
length
c
induc
gene
knockdown
wherea
bilesalt
deriv
fattyacid
conjug
longer
chain
length
enabl
potent
silenc
hepatocyt
via
hdl
receptor
anoth
exampl
possibl
introduc
benefici
modif
nucleic
acid
therapeut
come
antisens
drug
mipomersen
mipomersen
modifi
singlestrand
rna
molecul
target
apob
protein
implic
cardiovascular
diseas
isi
pharmaceut
report
promis
phase
ii
safeti
efficaci
result
phase
iii
trial
assess
efficaci
patient
famili
histori
hypercholesterolaemia
current
underway
joint
ventur
genzym
effect
macromolecul
undergo
increas
accumul
tumour
attribut
quickli
grow
tumour
vasculatur
improperli
form
subsequ
permeabl
larg
molecul
type
drug
deliveri
vehicl
made
lipid
nanocomplex
unilamellar
one
set
headgroup
multilamellar
two
set
headgroup
use
deliv
hydrophil
hydrophob
payload
depend
structur
tissu
cell
amen
deliveri
nake
chemic
modifi
sirna
deliveri
nanoparticl
incorpor
sirna
use
gener
deliveri
vehicl
design
facilit
uptak
target
tissu
interest
use
system
deliveri
protect
sirna
payload
inhibit
nonspecif
deliveri
highlight
sever
import
characterist
deliveri
nanoparticl
provid
specif
exampl
construct
use
surfac
properti
surfac
charg
deliveri
nano
particl
significantli
influenc
way
interact
target
cell
physiolog
molecul
simplifi
vitro
set
posit
charg
deliveri
vehicl
facilit
uptak
associ
neg
charg
cellular
membran
posit
charg
also
promot
complex
format
compress
polyanion
nucleic
acid
sirna
situat
howev
becom
complic
vivo
neg
charg
serum
protein
bloodstream
often
bind
posit
charg
nanocomplex
therefor
render
ineffect
addit
peg
hydrophil
conjug
surfac
deliveri
vehicl
assist
mitig
problem
addit
peg
conjug
control
particl
size
prevent
particl
aggreg
presenc
serum
coat
nanoparticl
hydrophil
molecul
peg
also
play
import
role
abil
sirna
deliveri
carrier
evad
immun
system
associ
phagocyt
peg
form
barrier
around
nanoparticl
provid
steric
stabil
protect
physiolog
surround
length
peg
chain
signific
influenc
stabil
protect
properti
chain
length
typic
optim
individu
deliveri
system
biodistribut
biodistribut
sirna
significantli
influenc
formul
deliveri
vehicl
system
administr
synthet
deliveri
nanoparticl
often
result
accumul
organ
reticuloendotheli
system
includ
liver
spleen
kidney
lung
coincid
much
success
sirna
deliveri
seen
recent
year
target
diseas
within
organ
excret
kidney
typic
occur
molecul
less
kda
size
nake
sirna
experi
rapid
renal
clearanc
upon
system
administr
sever
studi
monitor
biodistribut
sirna
mice
intraven
inject
observ
nake
sirna
accumul
kidney
urin
within
minut
administr
complex
sirna
synthet
materi
size
deliveri
nanoparticl
increas
avoid
glomerular
filtrat
kidney
reserv
sirna
altern
organ
target
addit
report
certain
sirna
formul
capabl
accumul
subcutan
tumour
phenomenon
attribut
enhanc
permeabl
retent
epr
effect
therefor
becom
common
approach
exploit
leaki
vasculatur
tumour
purpos
direct
deliveri
other
also
report
success
target
tumour
conjug
ligand
antibodi
toxic
even
efficaci
sirna
deliveri
agent
render
useless
provok
unaccept
toxic
either
cellular
system
level
viral
vector
among
first
vehicl
studi
sirna
deliveri
induc
unaccept
level
toxic
activ
immun
respons
therefor
synthet
lipid
polym
develop
offer
altern
viral
vector
nucleic
acid
deliveri
applic
care
formul
avoid
stimul
immun
system
clearanc
larger
molecular
mass
materi
typic
requir
biodegrad
use
biodegrad
high
molecular
mass
polyc
polym
contain
linkag
cleav
insid
cell
help
reduc
cytotox
synthet
materi
demonstr
potenti
effect
nonvir
sirna
deliveri
carrier
although
mani
type
compound
investig
potenti
candid
review
focus
synthet
materi
success
deliv
nucleic
acid
vivo
overview
deliveri
agent
present
found
tabl
liposom
lipidlik
materi
unilamellar
multilamellar
liposom
commonli
use
pharmaceut
deliveri
vehicl
aqueou
environ
certain
materi
abil
form
liposom
lipid
bilay
form
sphere
aqueou
core
exampl
one
set
polar
headgroup
creat
outer
surfac
nanocomplex
anoth
set
polar
headgroup
face
interior
hydrophil
core
hous
nucleic
acid
payload
fig
also
possibl
liposom
amorph
structur
lipid
nucleic
acid
interspers
throughout
liposom
creat
use
singl
multipl
type
lipid
allow
addit
flexibl
optim
physic
chemic
properti
nanoparticl
liposom
use
deliveri
nucleic
acid
year
origin
studi
felgner
colleagu
detail
abil
cation
lipid
dotma
n
propyl
n
n
ntrimethlyl
ammonium
chlorid
deliv
dna
rna
mous
rat
human
cell
line
recent
stabl
nucleic
acidlipid
particl
snalp
formul
demonstr
efficaci
sever
model
vivo
studi
morrissey
cowork
indic
hbv
replic
inhibit
deliveri
sirnasnalp
complex
target
hbv
rna
three
daili
intraven
inject
mg
per
kg
per
day
reduc
serum
hbv
level
least
one
order
magnitud
effect
specif
dosedepend
last
day
dose
addit
zimmerman
colleagu
demonstr
abil
snalp
enabl
knockdown
apob
liver
cynomolgu
monkey
singl
sirna
inject
result
dosedepend
silenc
apob
mrna
express
liver
hour
administr
maxim
silenc
knockdown
confirm
caus
apob
mrna
cleavag
precis
site
predict
rnai
mechan
persist
day
highest
administ
dose
mg
per
kg
addit
studi
detail
use
snalp
formul
combat
zair
strain
ebola
viru
prove
fatal
victim
via
haemorrhag
fever
contain
within
snalp
formul
sirna
target
polymeras
gene
viru
complet
protect
guinea
pig
viraemia
death
administ
shortli
ebola
viru
challeng
import
note
preliminari
studi
mice
indic
activ
interferon
suggest
stimul
immun
system
may
also
role
efficaci
recent
sato
cowork
use
vitaminacoupl
lipotrust
liposom
deliv
sirna
fibrogen
hepat
cell
treatment
liver
cirrhosi
five
administr
sirna
lipocomplex
report
resolv
liver
fibrosi
prolong
surviv
rat
otherwis
lethal
liver
cirrhosi
doseand
durationdepend
manner
also
shown
rescu
relat
offtarget
effect
associ
recruit
innat
immun
system
use
lipid
complex
local
sirna
administr
also
prove
benefici
vagin
instil
cation
liposom
compris
oligofectamin
sirna
target
herp
simplex
viru
hsv
reportedli
led
uptak
epitheli
lamina
propria
cell
vagina
mice
protect
lethal
infect
day
sirna
complex
protect
mice
administ
andor
otherwis
lethal
challeng
anoth
studi
intrathec
administr
complex
formul
ifect
sirna
protect
mice
fatal
japanes
enceph
viru
west
nile
viru
intracrani
administr
reduc
pain
receptor
express
follow
intrathec
administr
rat
also
note
sever
synthet
lipidbas
materi
demonstr
dna
transfect
effici
similar
materi
may
also
potenti
serv
candid
sirna
deliveri
given
similar
involv
two
type
nucleic
acid
deliveri
exampl
wheeler
et
al
use
liposom
compris
combin
cation
lipid
gapdlri
n
n
dodecyloxi
bromid
neutral
colipid
dope
dioleoylphosphatidylethanolamin
transfect
mous
lung
gene
confer
chloramphenicol
resist
singl
intranas
administr
gene
express
enhanc
rel
plasmid
dna
alon
follow
gradual
return
baselin
level
day
postadministr
also
interest
transactiv
transcript
activ
tat
modifi
liposom
complex
gene
encod
green
fluoresc
protein
gfp
inject
local
induc
express
gfp
lewi
lung
carcinoma
tumour
cell
mice
although
liposom
among
popular
nucleic
acid
deliveri
agent
concern
regard
safeti
therapeut
use
remain
toxic
certain
cation
lipid
particl
report
vitro
vivo
certain
synthet
agent
found
induc
gene
signatur
might
increas
offtarget
effect
sirna
despit
issu
liposom
show
promis
futur
clinic
use
evidenc
approv
pegyl
liposom
doxorubicin
amphotericin
b
deliveri
us
food
drug
administr
anoth
studi
combinatori
librari
lipidlik
materi
develop
use
sirna
deliveri
lipidoid
synthes
conjug
addit
alkylacryl
amid
primari
secondari
amin
studi
cell
cultur
one
lead
candid
vivo
gene
knockdown
identifi
compris
five
alkylacrylamid
chain
attach
amin
core
fig
formul
materi
sirna
capabl
achiev
potent
persist
silenc
variou
lung
liver
target
mice
rat
cynomolgu
monkey
recent
primat
studi
also
use
deliv
sirna
protein
regul
ldl
receptor
protein
level
function
liverspecif
sirna
silenc
reduc
mrna
level
mice
rat
well
reduc
human
transcript
level
transgen
mice
silenc
persist
week
singl
intraven
dose
indic
complex
may
serv
potent
effect
treatment
hypercholesterolaemia
importantli
lipidoid
materi
shown
facilit
sirna
deliveri
without
disrupt
endogen
microrna
process
final
gene
express
liver
encod
protein
haem
oxygenas
also
silenc
mice
sirna
nanoparticl
formul
lipidoid
knockdown
may
repres
potenti
approach
treatment
malaria
infect
diseas
progress
polym
cation
polym
linear
branch
structur
serv
effici
transfect
agent
abil
bind
condens
larg
nucleic
acid
stabil
nanoparticl
materi
also
shown
stimul
nonspecif
endocytosi
well
endosom
escap
propos
mechan
protonspong
effect
wherebi
buffer
endosom
lead
accumul
ion
within
compart
osmot
pressur
eventu
burst
endosom
pei
broadli
investig
deliveri
carrier
administr
wide
rang
nucleotidebas
therapi
includ
dna
sirna
oligonucleotid
also
frequent
use
variou
local
sirna
deliveri
applic
intrathec
administr
peisirna
complex
report
select
knockdown
pain
receptor
rat
maxim
effect
occur
day
mrna
level
day
associ
protein
level
follow
inject
mg
sirna
target
subunit
nmda
nmethyldaspart
receptor
pei
also
shown
efficaci
subcutan
mous
tumour
model
intraperiton
administr
complex
sirna
led
deliveri
intact
sirna
tumour
mark
reduct
tumour
growth
sirnamedi
downregul
human
epiderm
growth
factor
also
known
signific
concern
regard
toxic
pei
higher
molecular
mass
high
dose
howev
strategi
modifi
structur
pei
reduc
toxic
retain
potent
abil
transfect
cell
develop
cyclodextrin
polym
also
develop
sirna
deliveri
agent
tumour
growth
mous
model
metastat
ewe
sarcoma
shown
inhibit
system
deliveri
nanoparticl
form
cyclodextrin
target
ligand
transferrin
sirna
specif
fusion
gene
commonli
associ
condit
knockdown
observ
upon
remov
target
ligand
evid
immun
stimul
toxic
anoth
studi
heidel
cowork
use
agerel
macular
degener
amd
diseas
eye
caus
excess
growth
ruptur
blood
vessel
within
cornea
lead
caus
blind
sever
earli
sirna
clinic
trial
target
diseas
primarili
due
eas
local
deliveri
eye
fig
studi
effect
sirna
deliveri
immun
system
cynomolgu
monkey
specif
sirna
target
subunit
ribonucleotid
reductas
deliv
intraven
escal
dose
establish
multipl
system
dose
target
nanoparticl
contain
nonchem
modifi
sirna
safe
administ
nonhuman
primat
addit
cyclodextrintransferrin
nanoparticl
demonstr
efficaci
knock
luciferas
ribonucleotid
reductas
gene
mice
polymersirna
conjug
also
shown
potenti
applic
system
sirna
deliveri
rozema
et
al
develop
polymerconjug
deliveri
system
call
dynam
polyconjug
facilit
deliveri
sirna
hepatocyt
key
featur
dynam
polyconjug
technolog
includ
membraneact
cation
polym
abil
revers
mask
activ
polym
reach
acid
environ
endosom
abil
target
modifi
polym
sirna
cargo
specif
hepatocyt
intraven
inject
dynam
polyconjug
capabl
induc
knockdown
two
mous
liver
gene
analys
serum
liver
enzym
cytokin
level
treat
mice
indic
sirna
complex
form
synthet
polym
well
toler
today
sirna
therapeut
progress
clinic
tabl
mani
advanc
trial
reli
form
local
deliveri
although
sever
ongo
clinic
trial
involv
use
deliveri
agent
includ
tabl
mani
formul
preclin
animalstudi
phase
major
pharmaceut
compani
develop
sirna
therapeut
sever
advanc
clinic
trial
focu
treatment
agerel
macular
degener
amd
lead
caus
blind
amd
aris
excess
bloodvessel
growth
ruptur
within
cornea
nake
sirna
target
gene
vascular
endotheli
growth
factor
vegf
receptor
vegfr
shown
therapeut
potenti
inhibit
excess
vascular
eye
lead
amd
first
clinic
trial
involv
sirna
carri
acuiti
pharmaceut
treatment
amd
complet
phase
ii
trial
report
dose
well
toler
lack
advers
system
effect
test
move
phase
iii
trial
taken
opko
health
allergan
current
conduct
phase
ii
clinic
trial
sirna
amd
complet
phase
result
indic
minim
side
effect
improv
vision
patient
although
silenc
therapeut
also
sirna
product
amd
pipelin
refocus
phase
ii
clinic
studi
treatment
diabet
macular
oedema
anoth
condit
caus
leaki
vasculatur
within
eye
importantli
recent
studi
report
antivegf
sirna
efficaci
eye
due
specif
gene
silenc
instead
caus
nonspecif
stimul
pathway
reduc
angiogenesi
although
studi
call
question
natur
antiangiogen
effect
report
amd
clinic
trial
explain
therapeut
effect
observ
applic
sirna
appropri
control
perform
also
note
alnylam
formul
target
nucleocapsid
n
gene
rsv
major
caus
respiratori
ill
infant
young
children
formul
complet
phase
trial
found
well
toler
healthi
adult
sinc
phase
ii
trial
demonstr
signific
antivir
efficaci
formul
adult
move
forward
expect
synthet
nanoparticl
compos
polym
lipid
lipidoid
conjug
key
role
system
applic
sirna
clinic
incorpor
tissuespecif
ligand
particl
may
enabl
target
assist
vivo
biodistribut
deliveri
also
anticip
futur
develop
requir
attent
nonspecif
activ
immun
system
sirna
includ
pathway
given
potenti
nonspecif
effect
import
therapeut
mode
action
valid
possibl
direct
measur
target
mrna
level
vivo
chemic
modif
sirna
substitut
minim
nonspecif
effect
expect
addit
improv
activ
deliveri
mediat
direct
chemic
modif
sirna
sequenc
summari
field
rnai
therapeut
made
signific
progress
sinc
first
demonstr
gene
knockdown
mammalian
cell
sirnabas
formul
offer
signific
potenti
therapeut
agent
induc
potent
persist
specif
silenc
broad
rang
genet
target
deliveri
remain
signific
barrier
widespread
use
rnai
therapeut
clinic
set
futur
work
focus
develop
safe
effect
deliveri
materi
need
ensur
broadest
applic
rnai
clinic
